Document text
Principal Investigator: Lesia Dropulic
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2023
Award: $1,923,376
Funding agency: National Institute of Allergy and Infectious Diseases
The purpose of this Vaccine Research Center (VRC) Clinical Trials Program (CTP) project is to screen volunteers for protocols that involve the administration of investigational agents and to collect human specimens, such as blood, mucosal secretions, skin swabs, skin biopsy, or other body fluids, and in some circumstances perform radiographic imaging and clinical evaluations, to support laboratory research studies and to validate research assays used in evaluation of clinical trials immunogenicity results. These samples and data are used by laboratory researchers in their work on the development of vaccines and monoclonal antibodies targeting HIV and other emerging infectious diseases, to study the correlates of immunity related to infectious diseases, and in laboratory work related to the development and/or validation of immunological assays. To carry out research studies, it is sometimes necessary to obtain larger quantities of plasma or mononuclear cells than can be safely obtained by simple phlebotomy. These blood components can be safely obtained using apheresis procedures, which are performed in the NIH Clinical Center Department of Transfusion Medicine. During FY23, healthy volunteers have been enrolled in the VRC/CTP screening protocol (VRC 500) to assess healthy volunteers for eligibility in the following trials: a next-generation HIV monoclonal antibody targeting the HIV envelope CD4 binding site; a novel mRNA Nipah virus vaccine; and a novel hexavalent mosaic nanoparticle influenza vaccine. In addition, a new effort to collect samples by fine-needle aspiration of an axillary lymph node after influenza vaccination was implemented under the specimen collection protocol VRC 900 with the goal of understanding evolution of the B cell response after vaccination.
Terms: <AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Apheresis><Assay><Axillary Lymph Node><Axillary Node><Axillary lymph node group><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Binding Sites><Bioassay><Biologic Assays><Biologic Factor><Biological Assay><Biological Factors><Biopsy><Blood><Blood Component Removal><Blood Plasma><Blood Reticuloendothelial System><Body Fluids><Body Tissues><Cell Body><Cells><Cellular Immune Function><Clinical Evaluation><Clinical Testing><Clinical Treatment Moab><Clinical Trials><Combining Site><Communicable Diseases><Correlation Studies><Data><Development><Eligibility><Eligibility Determination><Emerging Communicable Diseases><Emerging Infectious Diseases><Enrollment><Evolution><FNA><Fine Needle Aspirate><Fine needle aspiration biopsy><Fine-Needle Aspiration><Flu vaccination><Goals><HIV><HIV envelope><HIV envelope protein><Hemapheresis><Human><Human Immunodeficiency Viruses><Image Analyses><Image Analysis><Immune><Immune response><Immunes><Immunity><Immunological response><Immunology procedure><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Influenza Vaccines><Influenza immunization><Influenza vaccination><Investigators><LAV-HTLV-III><Laboratories><Laboratory Research><Licensing><Lymphadenopathy-Associated Virus><Messenger RNA><Methods><Modern Man><Monoclonal Antibodies><Mononuclear><Mucosa><Mucosal Tissue><Mucous Membrane><NIH><National Institutes of Health><Nipah Virus><Pathogenesis><Pheresis><Phlebotomy><Plasma><Plasma Serum><Procedures><Prophylactic vaccination against influenza><Protocol><Protocol Screening><Protocols documentation><Radiography><Reactive Site><Research><Research Personnel><Research Specimen><Researchers><Reticuloendothelial System, Serum, Plasma><Roentgenography><Sampling><Severity of illness><Skin><Specimen><Statistical Correlation><Swab><Tissues><United States National Institutes of Health><Vaccinated><Vaccination><Vaccine Clinical Trial><Vaccine Research><Vaccines><Validation><Venous blood sampling><Viral Diseases><Virus Diseases><Virus-HIV><Work><clinical center><clinical test><develop a vaccine><develop vaccines><development of a vaccine><developmental><disease severity><enroll><experience><flu immunisation><flu vaccine><flu virus vaccine><healthy volunteer><host response><image evaluation><image interpretation><immune function><immune system response><immunogenicity><immunologic assay><immunologic assay/test><immunoresponse><influenza virus vaccination><influenza virus vaccine><mAbs><mRNA><monoclonal Abs><mosaic><nano particle><nano-sized particle><nanoparticle><nanosized particle><next generation><novel><programs><radiologic imaging><radiological imaging><recruit><research clinical testing><research study><response><sample collection><screening><screening program><screenings><specimen collection><transfusion medicine><vaccination against influenza><vaccination protocol><vaccine against flu><vaccine against influenza><vaccine antibodies><vaccine candidate><vaccine development><vaccine induced antibodies><vaccine protocol><vaccine-induced antibodies><vaccine-related research><validations><viral infection><virus infection><virus-induced disease><volunteer>